Improved outcome with high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed aggressive B-cell non-Hodgkin's lymphomas (NHL): The impact of histologies of follicular (FL) origin.

被引：0
|
作者：
Khouri, IF [1 ]
Saliba, RM [1 ]
Acholonu, S [1 ]
Okoroji, GJ [1 ]
Hosing, C [1 ]
Fayad, L [1 ]
Couriel, DR [1 ]
Pro, B [1 ]
Giralt, S [1 ]
Andersson, B [1 ]
Younes, A [1 ]
McLaughlin, P [1 ]
Champlin, RE [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2716
引用
收藏
页码：735A / 736A
页数：2
相关论文
共 50 条
  • [1] Concurrent administration of high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed B-cell lymphomas: Increased efficacy without added toxicity.
    Khouri, IF
    Saliba, RM
    Hosing, C
    Okoroji, GJ
    Donato, ML
    Younes, A
    Acholonu, S
    McLaughlin, P
    Andersson, B
    Rodriguez, MA
    Korbling, M
    Cabanillas, F
    Champlin, R
    BLOOD, 2002, 100 (11) : 645A - 645A
  • [2] High-dose versus standard-dose rituximab with BEAM in autologous stem cell transplantation (SCT) for relapsed aggressive b-cell non-Hodgkin's lymphomas (NHL).
    Srour, Samer Ali
    Khouri, Issa F.
    Nieto, Yago
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Anderlini, Paolo
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Hosing, Chitra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMAS (NHL)
    Srour, S. A.
    Lozano, S.
    Nieto, Y.
    Alousi, A. M.
    Popat, U. R.
    Quazilbash, M. H.
    Anderlini, P.
    Kebriaei, P.
    Shpall, E.
    Champlin, R. E.
    Hosing, C.
    HAEMATOLOGICA, 2016, 101 : 114 - 114
  • [4] Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Khouri, IF
    Saliba, RM
    Hosing, C
    Okoroji, GJ
    Acholonu, S
    Anderlini, P
    Couriel, D
    De Lima, M
    Donato, ML
    Fayad, L
    Giralt, S
    Jones, R
    Korbling, M
    Maadani, F
    Manning, JT
    Pro, B
    Shpall, E
    Younes, A
    McLaughlin, P
    Champlin, RE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2240 - 2247
  • [5] High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era
    Ban-Hoefen, Makiko
    Friedberg, Jonathan W.
    Kelly, Jennifer L.
    Bernstein, Steven H.
    Liesveld, Jane L.
    Young, Faith
    Fisher, Richard I.
    Constine, Louis
    Becker, Michael
    Phillips, Gordon L., II
    BLOOD, 2010, 116 (21) : 992 - 992
  • [6] Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma
    Kriegsmann, Katharina
    Rieger, Michael
    Schwarzbich, Mark-Alexander
    Sitter, Soeren
    Kriegsmann, Mark
    Bruckner, Thomas
    Hensel, Manfred
    Ho, Anthony Dick
    Witzens-Harig, Mathias
    Wuchter, Patrick
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 12 - 20
  • [7] A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results
    Srour, Samer A.
    Li, Shaoying
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Lozano-Cerrada, Sara
    Maadani, Farzeneh
    Alousi, Amin
    Kebriaei, Partow
    Anderlini, Paolo
    Nieto, Yago
    Jones, Roy
    Shpall, Elizabeth
    Champlin, Richard E.
    Hosing, Chitra
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (04) : 561 - 570
  • [8] Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)
    Khouri, Issa F.
    Turturro, Francesco
    Milton, Denai R.
    Korbling, Martin
    Samuels, Barry I.
    Jabbour, Elias J.
    Ledesma, Celina
    Valverde, Rosamar B.
    Gao, Hui
    Fanale, Michelle A.
    Fayad, Luis E.
    Nastoupil, Loretta J.
    Reuben, James M.
    Gulbis, Alison M.
    BLOOD, 2016, 128 (22)
  • [9] Autologous stem cell (AUTO) vs. non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HD-R) - Containing conditioning regimens for relapsed chemosensitve follicular lymphoma (FL).
    Khouri, IF
    Saliba, RM
    Hosing, CM
    Acholonu, SA
    Fayad, LE
    Korbling, MJ
    Saenz, C
    Pro, B
    Samuels, BI
    de Lima, MJ
    Giralt, SA
    Younes, A
    McLaughlin, PW
    Champlin, RE
    BLOOD, 2005, 106 (11) : 19A - 19A
  • [10] High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)
    Oyan, B
    Koc, Y
    Ozdemir, E
    Kansu, E
    BLOOD, 2004, 104 (11) : 393B - 393B
12345